products competing in the $40B consumer segment --> 0.05 --> $43M LTM revenue --> $19B TAM) -->

Wednesday, December 11, 2019 BiopharmaWatch Research 1 min read

Key Takeaway: products competing in the $40B consumer segment --> 0.05 --> $43M LTM revenue --> $19B TAM) -->

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice

Cash runway

~16 mo

Low dilution risk

Lead asset

NT0102

Phase 3 · Attention Deficit Hyperactivity Disorder (ADHD)

products competing in the $40B consumer segment --> 0.05 --> $43M LTM revenue --> $19B TAM) -->